Merrill says MedImmune still neutral

MedImmune Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating despite positive results reported by the company on the ability of CAIV-T, a nasal flu vaccine, to reduce flu incidence versus the injectable flu vaccine. Data was solid, but challenges include the ability to get approval for kids under age 2 due to 60% increase in wheezing, which represents 10% to 15% of the market and the price of the vaccine is likely to be double the injectable flu vaccine, a major marketing issue of FluMist previously. Merrill raised 2007 estimates of CAIV-T sales to $163 million from $157 million. Earnings per share for 2007 were increased to $0.97 from $0.93 per share. Shares of the Gaithersburg, Md., biotechnology company were up $1.55, or 4.54%, at $35.71 on volume of 5,029,304 shares versus the three-month running average of 2,726,690 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.